Furthermore, the enhanced LPI response was significantly diminished by a TLR2 inhibitor, but not by a TLR4 inhibitor (Figure 6(b)), indicating that TLR2 plays a major role in the platelet activation pathway in MPN. The gene discussed is TLR2; the disease is myeloproliferative neoplasm.